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The relative strengths and weakness of academia and industry in the skills 
necessary to bring a molecule forward to an approved drug are widely 
appreciated.  Indeed, the efficiency of moving to a modular approach to drug 
discovery and development—with modules drawn at different stages from 
diverse sectors and geographies—has been realized in the altruistic sector.  
However, conversion of this approach to the for–profit sector requires a 
revision of our thinking on intellectual property (IP). 
The potential value of too many molecules remains locked in company 
freezers, while exploitation of biological insights in academia is classically 
limited by the lack of tool compounds and of translational infrastructure to 
convert such leads into approved drugs.  Segregating these opportunities from 
each other are unrealistic expectations of IP rewards by both academia and 
industry, and an outmoded and inefficient approach to IP by both parties.  While 
some progress has been made with respect to academic infrastructure via 
clinical and translational science awards; and, industry has begun to make 
widespread but essentially limited deals with universities, it is worth 
considering the fundamentals of IP. 
Despite the odds of a new molecular entity becoming an approved drug 
being extremely long, the dominant IP is vested in chemical composition of 
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matter.  In the era of large vertically integrated companies—now on the wane—
this did not really matter.  The chemist, the expert in model systems and the 
clinical trialist all worked for the sponsoring company and all would profit via 
its stock shares if the drug was approved.  In an era of modular drug discovery 
and development, the trick will be to engage the best investigators at various 
stages in the process, despite them working in a different public or private entity 
than the originator of the chemical matter in question.  Provision of the funds 
to do their bit of the research will be insufficient; if they are best in brand they 
will have plenty of resources to conduct the research that is their own priority.  
Rather, they need to be incentivized by a piece of the action—some of the profit 
derived from an approved drug. 
As suggested recently,6 one approach would be to model prospectively the 
hurdles in the process and to apportion value—in terms of a share in the 
profits—to overcoming them on the way to drug approval.  This has the 
attraction of postponing the statement of value until it is actually realized.  It 
shifts the dominant IP from an entity with perhaps a 1:40,000 chance of having 
commercial value to something that actually has value.  Of course, real life will 
depart from the prospective model, but the model can be adjusted in Bayesian 
fashion as the process proceeds, so that at its conclusion, the model will 
recapitulate the relative challenge of the hurdles along the way and apportion 
value appropriately to their being overcome.  This approach requires an initial 
pot of money—potentially from diverse funders who may set the “grand 
challenge”—and prospective agreement on the part of contributions to their 
reward being subject to the modeling exercise. 
     We are used to modeling—3d structures, pharmacokinetics, and market 
value—at many stages of drug development; perhaps we should extend it to the 
domain of IP. 
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